Jamie L. Lesnock
Expertise in
12
conditions

Dr. Jamie L. Lesnock

Oncology
103 Transit Drive, 
Uniontown, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Expertise in
12
conditions
103 Transit Drive, 
Uniontown, PA 

Overview

Jamie Lesnock, MD, specializes in gynecologic oncology and is certified in gynecologic oncology and obstetrics and gynecology by the American Board of Obstetrics and Gynecology. She practices at University of Pittsburgh Physicians, Department of Obstetrics and Gynecology and is affiliated with UPMC Mercy, UPMC Presbyterian, UPMC Shadyside, UPMC Magee-Womens Hospital, and UPMC Passavant. She completed her residency at University of Pittsburgh School of Medicine and her medical degree at Vanderbilt University School of Medicine.

Dr. Lesnock is highly rated in 12 conditions, according to our data. Her top areas of expertise are Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Ureteral Reconstruction.

Her clinical research consists of co-authoring 42 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution

Vanderbilt University School Of Medicine

Residency

University of Pittsburgh School of Medicine

Specialties

Oncology

Licenses

Obstetrics & Gynecology in PA

Board Certifications

American Board Of Obstetrics And Gynecology
American Board Of Obstetrics And Gynecology

Fellowships

University of Pittsburgh School of Medicine

Hospital Affiliations

Magee Womens Hospital Of Upmc Health System
Upmc Presbyterian Shadyside
Uniontown Hospital
Upmc Altoona
The Washington Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UPMC Magee-Womens Gynecologic Oncology
103 Transit Drive, Uniontown, PA 15401
Other Locations
UPMC Magee-Womens Gynecologic Oncology
300 Halket Street, Pittsburgh, PA 15213
UPMC Magee-Womens Gynecologic Oncology
104 Wellness Way, Building 2, Washington, PA 15301
UPMC Magee-Womens Gynecologic Oncology
1300 Oxford Drive, Suite 2400, Bethel Park, PA 15102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: August 29, 2025
Intervention Type: Biological
Study Phase: Phase 2
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 03, 2024
Intervention Type: Other, Procedure
Study Phase: Not Applicable
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
Enrollment Status: Completed
Publish Date: September 01, 2022
Intervention Type: Other
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 8 Less Clinical Trials

42 Total Publications

ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
ASCO neoadjuvant chemotherapy in ovarian cancer guideline: A SGO endorsement.
Journal: Gynecologic oncology
Published: October 14, 2025
Similar Doctors
Nathan Bahary
Expertise in
18
conditions
Dr. Nathan Bahary
Oncology
Expertise in
18
conditions
Dr. Nathan Bahary
Oncology

Allegheny General Hospital

320 E North Ave, 
Pittsburgh, PA 
 (2.6 miles away)
412-359-6391
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nathan Bahary is an Oncologist in Pittsburgh, Pennsylvania. Dr. Bahary is highly rated in 18 conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Expertise in
23
conditions
Dr. Leonard Appleman
Oncology
Expertise in
23
conditions
Dr. Leonard Appleman
Oncology

Office

5150 Centre Ave, 
Pittsburgh, PA 
 (1.5 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is highly rated in 23 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and WT1-Related Wilms Tumor Syndromes.

Jason Luke
Expertise in
12
conditions
Dr. Jason Luke
Oncology
Expertise in
12
conditions
Dr. Jason Luke
Oncology

UPMC Presbyterian

200 Lothrop St, 
Pittsburgh, PA 
 (0.4 miles away)
412-383-1370
Languages Spoken:
English
See accepted insurances

Jason Luke is an Oncologist in Pittsburgh, Pennsylvania. Dr. Luke is highly rated in 12 conditions, according to our data. His top areas of expertise are Melanoma, Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, and Liver Embolization.

Frequently Asked Questions about Dr. Jamie L. Lesnock

How do I make an appointment with Dr. Jamie L. Lesnock?

You can book an appointment with Dr. Jamie L. Lesnock by calling their office at 412-663-6008. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jamie L. Lesnock a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jamie L. Lesnock is classified as an Elite expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jamie L. Lesnock specialize in?

While Dr. Jamie L. Lesnock is a Oncology, they have specific expertise in Endometrial Cancer, Ovarian Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jamie L. Lesnock participate in research or clinical trials?

Yes. Dr. Jamie L. Lesnock has published 42 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Jamie L. Lesnock's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jamie L. Lesnock accept my insurance?

Dr. Jamie L. Lesnock accepts most major insurance plans, including Aetna and Change Healthcare. We recommend calling the office directly at 412-663-6008 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lesnock's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 45 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile